Cargando…

Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity

SIMPLE SUMMARY: Advanced therapies have provided substantial clinical benefits in oncology, but low response rates in lung cancer patients remain challenging. Using preclinical models of human lung cancer, we investigated the anti-tumor potency of nanomedicine-based gene delivery for the tumor suppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Sang-Soo, Doherty, Caroline, Moghe, Manish, Rait, Antonina, Pirollo, Kathleen F., Harford, Joe B., Chang, Esther H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600612/
https://www.ncbi.nlm.nih.gov/pubmed/36291878
http://dx.doi.org/10.3390/cancers14205092
_version_ 1784816886503964672
author Kim, Sang-Soo
Doherty, Caroline
Moghe, Manish
Rait, Antonina
Pirollo, Kathleen F.
Harford, Joe B.
Chang, Esther H.
author_facet Kim, Sang-Soo
Doherty, Caroline
Moghe, Manish
Rait, Antonina
Pirollo, Kathleen F.
Harford, Joe B.
Chang, Esther H.
author_sort Kim, Sang-Soo
collection PubMed
description SIMPLE SUMMARY: Advanced therapies have provided substantial clinical benefits in oncology, but low response rates in lung cancer patients remain challenging. Using preclinical models of human lung cancer, we investigated the anti-tumor potency of nanomedicine-based gene delivery for the tumor suppressor RB94 and explored the mechanisms underlying its activity. This nanomedicine (scL-RB94) elicited significant anti-tumor responses reflecting enhanced tumor immunogenicity and reduced immunosuppression. The potential of scL-RB94 to improve outcomes in lung cancer patients is discussed. ABSTRACT: Because lung cancer remains the most common and lethal of cancers, novel therapeutic approaches are urgently needed. RB94 is a truncated form of retinoblastoma tumor suppressor protein with elevated anti-tumor efficacy. Our investigational nanomedicine (termed scL-RB94) is a tumor-targeted liposomal formulation of a plasmid containing the gene encoding RB94. In this research, we studied anti-tumor and immune modulation activities of scL-RB94 nanocomplex in preclinical models of human non-small cell lung cancer (NSCLC). Systemic treatment with scL-RB94 of mice bearing human NSCLC tumors significantly inhibited tumor growth by lowering proliferation and increasing apoptosis of tumor cells in vivo. scL-RB94 treatment also boosted anti-tumor immune responses by upregulating immune recognition molecules and recruiting innate immune cells such as natural killer (NK) cells. Antibody-mediated depletion of NK cells blunted the anti-tumor activity of scL-RB94, suggesting that NK cells were crucial for the observed anti-tumor activity in these xenograft models. Treatment with scL-RB94 also altered the polarization of tumor-associated macrophages by reducing immune-suppressive M2 macrophages to lower immune suppression in the tumor microenvironment. Collectively, our data suggest that the efficacy of scL-RB94 against NSCLC is due to an induction of tumor cell death as well as enhancement of innate anti-tumor immunity.
format Online
Article
Text
id pubmed-9600612
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96006122022-10-27 Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity Kim, Sang-Soo Doherty, Caroline Moghe, Manish Rait, Antonina Pirollo, Kathleen F. Harford, Joe B. Chang, Esther H. Cancers (Basel) Article SIMPLE SUMMARY: Advanced therapies have provided substantial clinical benefits in oncology, but low response rates in lung cancer patients remain challenging. Using preclinical models of human lung cancer, we investigated the anti-tumor potency of nanomedicine-based gene delivery for the tumor suppressor RB94 and explored the mechanisms underlying its activity. This nanomedicine (scL-RB94) elicited significant anti-tumor responses reflecting enhanced tumor immunogenicity and reduced immunosuppression. The potential of scL-RB94 to improve outcomes in lung cancer patients is discussed. ABSTRACT: Because lung cancer remains the most common and lethal of cancers, novel therapeutic approaches are urgently needed. RB94 is a truncated form of retinoblastoma tumor suppressor protein with elevated anti-tumor efficacy. Our investigational nanomedicine (termed scL-RB94) is a tumor-targeted liposomal formulation of a plasmid containing the gene encoding RB94. In this research, we studied anti-tumor and immune modulation activities of scL-RB94 nanocomplex in preclinical models of human non-small cell lung cancer (NSCLC). Systemic treatment with scL-RB94 of mice bearing human NSCLC tumors significantly inhibited tumor growth by lowering proliferation and increasing apoptosis of tumor cells in vivo. scL-RB94 treatment also boosted anti-tumor immune responses by upregulating immune recognition molecules and recruiting innate immune cells such as natural killer (NK) cells. Antibody-mediated depletion of NK cells blunted the anti-tumor activity of scL-RB94, suggesting that NK cells were crucial for the observed anti-tumor activity in these xenograft models. Treatment with scL-RB94 also altered the polarization of tumor-associated macrophages by reducing immune-suppressive M2 macrophages to lower immune suppression in the tumor microenvironment. Collectively, our data suggest that the efficacy of scL-RB94 against NSCLC is due to an induction of tumor cell death as well as enhancement of innate anti-tumor immunity. MDPI 2022-10-18 /pmc/articles/PMC9600612/ /pubmed/36291878 http://dx.doi.org/10.3390/cancers14205092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Sang-Soo
Doherty, Caroline
Moghe, Manish
Rait, Antonina
Pirollo, Kathleen F.
Harford, Joe B.
Chang, Esther H.
Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title_full Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title_fullStr Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title_full_unstemmed Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title_short Nanomedicine-Based Gene Delivery for a Truncated Tumor Suppressor RB94 Promotes Lung Cancer Immunity
title_sort nanomedicine-based gene delivery for a truncated tumor suppressor rb94 promotes lung cancer immunity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600612/
https://www.ncbi.nlm.nih.gov/pubmed/36291878
http://dx.doi.org/10.3390/cancers14205092
work_keys_str_mv AT kimsangsoo nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT dohertycaroline nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT moghemanish nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT raitantonina nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT pirollokathleenf nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT harfordjoeb nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity
AT changestherh nanomedicinebasedgenedeliveryforatruncatedtumorsuppressorrb94promoteslungcancerimmunity